{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:28:44Z","timestamp":1763504924989,"version":"3.45.0"},"reference-count":22,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":148,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As the accessibility of health services fluctuated throughout the COVID-19 pandemic, recommendations supporting off-label extended use of hormonal long-acting reversible contraceptive (LARC) devices began to appear around the globe. Supported by emerging evidence, these recommendations were intended to encourage consumers to postpone device replacement and reduce the need for face-to-face care interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based cohort study, data from the nationally representative Australian Pharmaceutical Benefits Scheme 10% sample were analysed. Specifically, logistic regression analysis was undertaken for females aged 15\u201349\u00a0years who had a hormonal LARC dispensed to them within the COVID-19 pandemic period (between February 2017 and November 2021) to assess timing of replacement, compared with timing for pre-COVID counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Extended use periods were observed in less than 10% of hormonal implant or intrauterine device users in both the pre- and post-COVID cohorts, with 40% replacing their device on time, and around 50% with no record of replacement. No statistically significant changes occurred after the onset of COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite recommendations for extending LARC device use periods, typical usage patterns were maintained in Australia throughout the COVID-19 pandemic. Given these extended use periods have since been made permanent in Australian clinical guidelines, targeted education for consumers and providers is likely to be required to ensure understanding, uptake and consistent implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh25004","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T19:40:36Z","timestamp":1750621236000},"source":"Crossref","is-referenced-by-count":0,"title":["Extending the use period of hormonal long-acting reversible contraceptive devices in Australia: exploring patterns of use in a cohort of users before and after COVID-19 guidance"],"prefix":"10.1071","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-4005","authenticated-orcid":true,"given":"Tahlee B.","family":"Stevenson","sequence":"first","affiliation":[{"name":"ASchool of Public Health, Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA 5000, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice R.","family":"Rumbold","sequence":"additional","affiliation":[{"name":"BSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Hall","sequence":"additional","affiliation":[{"name":"ASchool of Public Health, Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA 5000, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"Ilomaki","sequence":"additional","affiliation":[{"name":"CCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Vic 3052, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-7110","authenticated-orcid":true,"given":"Deborah","family":"Bateson","sequence":"additional","affiliation":[{"name":"DThe Daffodil Centre, Faculty of Medicine and Health, University of Sydney, Kings Cross, NSW 1340, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Mazza","sequence":"additional","affiliation":[{"name":"ESchool of Public Health and Preventive Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Vic 3004, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke E.","family":"Grzeskowiak","sequence":"additional","affiliation":[{"name":"BSAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia."},{"name":"FFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025111817261678500_R1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2165\/11591290-000000000-00000","article-title":"Efficacy and safety of long-acting reversible contraception.","volume":"71","author":"Stoddard","year":"2011","journal-title":"Drugs"},{"key":"2025111817261678500_R2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bpobgyn.2019.12.002","article-title":"Long-acting reversible contraceptive (LARCs) methods.","volume":"66","author":"Bahamondes","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2025111817261678500_R3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/ajo.13257","article-title":"Changes in use of hormonal long-acting reversible contraceptive methods in Australia between 2006 and 2018: a population-based study.","volume":"61","author":"Grzeskowiak","year":"2021","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2025111817261678500_R4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/ajo.12587","article-title":"Current barriers and potential strategies to increase the use of long-acting reversible contraception (LARC) to reduce the rate of unintended pregnancies in Australia: an expert roundtable discussion.","volume":"57","author":"Mazza","year":"2017","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2025111817261678500_R5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1363\/46e9020","article-title":"Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries.","volume":"46","author":"Riley","year":"2020","journal-title":"Int Perspect Sex Reprod Health"},{"key":"2025111817261678500_R6","unstructured":"Family Planning Alliance Australia. Extended use of an ongoing access to LARCs during the COVID-19 pandemic \u2013 Family Planning Alliance Australia Statement 2020; 2020. Available at https:\/\/familyplanningallianceaustralia.org.au\/wp-content\/uploads\/2023\/06\/LARCs-during-the-COVID-19-pandemic-FPAA-APR-2020.pdf [accessed March 2023]"},{"key":"2025111817261678500_R7","unstructured":"The Faculty of Sexual and Reproductive Healthcare. Essential services in sexual and reproductive healthcare; 2020. Available at https:\/\/bsacp.org.uk\/wp-content\/uploads\/2020\/03\/fsrh-position-essential-srh-services-during-covid19-24-march-2020.pdf [accessed March 2023]"},{"key":"2025111817261678500_R8","unstructured":"Mazza D. Women\u2019s Sexual and Reproductive Health COVID-19 Coalition Bulletin #3, 10th June 2020. SPHERE NHMRC Centre of Research Excellence in Sexual and Reproductive Health for Women in Primary Care; 2020. Available at https:\/\/mailchi.mp\/3121d6d142d1\/srh-covid-19-bulletin-5032793?e=6321eec329"},{"key":"2025111817261678500_R9","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"key":"2025111817261678500_R10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bmjsrh-2024-202224","article-title":"Longitudinal trends in uptake of hormonal long-acting reversible contraception devices throughout the COVID-19 pandemic: an Australian population-based study.","volume":"50","author":"Stevenson","year":"2024","journal-title":"BMJ Sex Reprod Health"},{"key":"2025111817261678500_R11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1071\/SH22109","article-title":"Sustaining sexual and reproductive health through COVID-19 pandemic restrictions: qualitative interviews with Australian clinicians.","volume":"19","author":"Newman","year":"2022","journal-title":"Sex Health"},{"key":"2025111817261678500_R12","doi-asserted-by":"publisher","first-page":"873.E1","DOI":"10.1016\/j.ajog.2022.09.007","article-title":"Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena extension trial.","volume":"227","author":"Jensen","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2025111817261678500_R13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.nwh.2023.06.005","article-title":"An integrative review of extended use of intrauterine devices.","volume":"27","author":"Harrison","year":"2023","journal-title":"Nurs Womens Health"},{"key":"2025111817261678500_R14","doi-asserted-by":"publisher","first-page":"586.e1","DOI":"10.1016\/j.ajog.2017.01.036","article-title":"Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device \u2013 two years beyond FDA-approved duration.","volume":"216","author":"McNichols","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025111817261678500_R15","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1093\/humrep\/dew222","article-title":"Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.","volume":"31","author":"Ali","year":"2016","journal-title":"Hum Reprod"},{"key":"2025111817261678500_R16","unstructured":"Therapeutic Goods Administration. Australian Product Information MIRENA\u00ae (levonorgestrel) intrauterine drug delivery system; 2024. Available at https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2009-PI-01235-3"},{"key":"2025111817261678500_R17","unstructured":"Therapeutic Goods Administration. Australian Product Information: Implanon NXT\u00ae Subdermal Implant; 2023. Available at https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2011-PI-02693-3"},{"key":"2025111817261678500_R18","unstructured":"The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). C-Gyn 3 Contraception \u2013 Category: Clinical Guideline (Signposting); 2024. Available at https:\/\/ranzcog.edu.au\/wp-content\/uploads\/Contraception-Clinical-Guideline.pdf"},{"key":"2025111817261678500_R19","unstructured":"The Faculty of Sexual and Reproductive Healthcare. FSRH Guideline \u2013 Intrauterine Contraception; 2025. Available at https:\/\/www.fsrh.org\/Common\/Uploaded%20files\/documents\/fsrh-clinical-guideline-intrauterine-contraception-mar-23-amended.pdf"},{"key":"2025111817261678500_R20","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-10991-4","article-title":"Offering extended use of the contraceptive implant via an implementation science framework: a qualitative study of clinicians\u2019 perceived barriers and facilitators.","volume":"24","author":"Rigler","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025111817261678500_R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2024.110483","article-title":"\u201cMy IUD is expiring\u201d: A national U.S. mystery client study regarding use of the LNG 52-mg IUD for pregnancy prevention beyond 5 years after multiple FDA extensions.","volume":"137","author":"de Oliveira","year":"2024","journal-title":"Contraception"},{"key":"2025111817261678500_R22","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2023.110038","article-title":"\u201cMy implant is expiring\u201d: a national US mystery shopper study regarding extended use of the contraceptive implant.","volume":"123","author":"Pai","year":"2023","journal-title":"Contraception"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25004\/1361753\/sh25004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25004\/1361753\/sh25004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:26:25Z","timestamp":1763504785000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/22\/4\/SH25004\/200634\/Extending-the-use-period-of-hormonal-long-acting"}},"subtitle":[],"editor":[{"given":"Phillip","family":"Keen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1071\/sh25004","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"type":"print","value":"1448-5028"},{"type":"electronic","value":"1449-8987"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"article-number":"SH25004"}}